Clinical trials in rheumatology

Area of Science:

• Clinical research methodology
• Evidence-based medicine
• Health outcomes research

Background:

• Randomized controlled trials (RCTs) are the gold standard for assessing clinical utility of interventions.
• RCTs significantly influence physician clinical practice.
• Increasing emphasis on comparative trials over placebo trials, with growing pharmaceutical industry funding.

Purpose of the Study:

• To highlight the importance of aligning RCT design and analysis with specific research questions.
• To discuss the evolving landscape of clinical trials, including the rise of comparative studies and industry funding.
• To examine the increasing attention on process and outcome measures and their standardization.

Main Methods:

• Review of current trends in clinical trial design and execution.
• Analysis of the shift towards comparative trials and industry-sponsored research.
• Discussion of efforts to define and standardize disease activity measures.

Main Results:

• Comparative trials have become more frequent than placebo trials in the last decade.
• Disease activity measures are being standardized, with significant progress in rheumatoid arthritis.
• Some common disease states are being neglected in the standardization process.

Conclusions:

• Ensuring RCTs are designed and analyzed to answer specific questions is crucial.
• Standardization of core outcome measures is advancing, but equitable attention across diseases is needed.
• The influence of pharmaceutical funding on clinical research warrants careful consideration.